-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Assumes Rapport Therapeutics at Buy, Raises Price Target to $56

Benzinga·05/19/2026 18:32:41
Listen to the news
Truist Securities analyst Danielle Brill assumes Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and raises Price Target to $56.